

## Immunosign<sup>®</sup> gene signature assesses LTX-315 ability to turn ‘cold’ tumors ‘hot’ at ASCO 2017

- Immune gene expression signature Immunosign<sup>®</sup> was applied to a set of pre and post LTX-315 treatment biopsies
- Immunosign<sup>®</sup> analysis of LTX-315 treated tumors shows clear effect on key genes involved in the immune-mediated tumor regression

Marseille, France, June 5, 2017 – HaliDx SAS, an immuno-oncology diagnostic company, announced the presentation of Phase I data from its partner Lytix Biopharma at the 2017 ASCO Meeting on LTX-315, a first in class oncolytic peptide reshaping the tumor microenvironment to induce a local and systemic effect in metastatic tumors. In this study, the HaliDx immune gene expression signature Immunosign<sup>®</sup> 21 has been key to score before and after induction of LTX-315, the expression level of key immune genes (effector T cell, Th1 orientation, chemokines, and cytokines) involved in immune-mediated tumor regression. This analysis has highlighted the clear effect of LTX-315 and its ability to turn ‘cold’ tumors ‘hot’ in cancer patients. Elevation of tumor infiltrating lymphocytes in injected lesions was observed in 14 of 19 (75%) evaluable patients:

- Immunosign<sup>®</sup> 21 profiles expression of a pre-defined set of effector T cell, Th1, chemokine, and cytokine genes
- Immunosign<sup>®</sup> 21 score was calculated with specified bioinformatics algorithm.

Immunosign<sup>®</sup> Clinical Research assays are sets of new immune gene expression signatures designed to investigate the immune response within the tumor environment. These assays can be used to predict or assess treatment efficacy in clinical studies.

**Vincent FERT, CEO of HaliDx comments:** *“We are delighted to team –up with Lytix to contribute to the Phase I development of this first in class therapeutic approach with our proprietary biomarker solutions. We are proud to bring to our Biopharma partners a unique view on the dynamic of the immune response to tumors and help assessing treatment efficacy.”*

**Professor Øystein Rekdal, CSO and co-founder of Lytix Biopharma AS comments:** *“HaliDx Immunosign 21 gene expression profiling technology has clearly and further characterized LTX-315’s ability to convert immunogenically “cold” tumors “hot” making LTX-315 an ideal combination treatment with immune checkpoint inhibitors”*

### Poster presentation:

- [LTX-315, an oncolytic peptide, to convert immunogenically ‘cold’ tumors to ‘hot’ in patients with advanced or metastatic tumours: Results from an ongoing phase I study](#)

**Abstract #3085**

**Poster Session:** Developmental Therapeutics – Immunotherapy

**Poster Board #180**

**Session Time/Location:** Monday, June 5, 2017: 8:00-11:30 AM CDT, Hall A

**Presenter:** James F. Spicer, Ph.D., King's College London, London, United Kingdom

## About HalioDx

### The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

HalioDx Immunoscore® technology integrates immunohistochemistry combined with advanced imaging analysis enabling extraction of spatially-organized tissue molecular information.

Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression.

Pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, Immunoscore® Colon is the flagship assay of HalioDx, positioned to be a future diagnostic standard for delivering prognostic and predictive information. HalioDx develops also Halioseek™ PD-L1/CD8 and Immunosign®, proprietary gene signatures based assay, to help stratifying patients for immunotherapies.

HalioDx collaborates with an increasing number of renowned international clinical groups and biopharmaceutical companies to support clinical utility and ensure rigorous performance validation of its assays in a large number of cancer indications.

HalioDx has an experienced team of more than 100 employees, a CLIA-certified laboratory (H1 2017) and compliant facilities to develop, manufacture, register and market *in vitro* diagnostic (IVD) products.

HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies.

The company co-founded the European immunology cluster Marseille Immunopole (MI).

For more information, please visit our website [www.halioldx.com](http://www.halioldx.com) and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

## Contacts

### HalioDx SAS

#### Vincent Fert

President and CEO

+ 33 (0)4 91 29 30 90

[vincent.fert@haliodx.com](mailto:vincent.fert@haliodx.com)

### ATCG Press

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Jean-Mehdi Grangeon (ROW)

Mob: +33 (0)6 62 22 00 24

[halioldx@atcg-partners.com](mailto:halioldx@atcg-partners.com)